According to the latest BCG report 'The GenAI Adoption Conundrum', over 80 per cent of developers acknowledge its advantages, ...

ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

The list of what is on top of our mind is much broader than in the past,” says Christophe Weber, Takeda’s president and CEO, ...

Rising temperature and growing threat of climate change may increase default risk in 30 per cent of agri and housing loans portfolio in the next five years, according to an analysis by BCG. According ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

The platform can be harnessed for TB, potentially improving protection and durability of immunity in a way that traditional ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.

BCG predicts rising temperatures will increase default risk in 30% of agri and housing loans by 2030, highlighting climate ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials ...

In a tight economy, disciplined cost management is often a better path than absorbing margin pressures or passing costs to ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...